106. Pandemic Pinch: The Impact of COVID Response on Antimicrobial Stewardship Program (ASP) Resource Allocation
Authors: Ashley Elizabeth Dodds , Dyer April , Jones Travis M , Johnson Melissa D , Davis Angelina , Foy Katherine R , Nelson Alicia , Advani Sonali D , Advani Sonali D , Cromer Andrea , Doughman Danielle , Akinboyo Ibukunoluwa , Sickbert-Bennett Emily , Moehring Rebekah W , Anderson Deverick J , Spires Steven S 
Published: December 2021

Abstract

Background
The COVID-19 pandemic placed a strain on inpatient clinical and hospital programs due to increased patient volume and rapidly evolving data on best COVID-19 management strategies. However, the impact of the pandemic on ASPs has not been well described.

Methods
We performed a cross-sectional electronic survey of stewardship pharmacy and physician leaders in 37 hospitals within the Duke Antimicrobial Stewardship Outreach Network (DASON) (community) and Duke/UNC Health systems (academic) in April-May 2021. The survey included 60 questions related to staffing changes, use of COVID-targeted therapies, related restrictions, and medication shortages.

Results
Twenty-seven facilities responded (response rate of 73%). Pharmacy personnel was reduced in 17 (63%) facilities by an average of 16%. Impacted pharmacy personnel included the stewardship lead in 15/17 (88.2%) hospitals. Converting to remote work was rare and only reported in academic institutions (n=2, 7.4%). ASP personnel were reassigned to non-stewardship duties in 12 (44%) hospitals with only half returning to routine ASP work as of May 2021. Respondents estimated that 62% of routine ASP activities were diverted during the time of the pandemic. Non-traditional, pandemic-related ASP activities included managing multiple drug shortages, of which ventilator support medications (91%) were most common affecting patient care at 52% of facilities. Steroid and hydroxychloroquine shortages were less frequent (44% and 22%, respectively). Despite staff reductions, pharmacists often served as primary contact for remdesivir approvals either using a criteria-based checklist at dispensing or as part of a dedicated phone approval team (Figure). Most (77%) hospitals used a criteria-based pharmacist review strategy after remdesivir FDA approval. Restriction processes for other COVID-19 therapies such as tocilizumab, hydroxychloroquine, and ivermectin were reported in 64% of hospitals.
Remdesivir Allocation Strategy

Proportion of facilities implementing specific remdesivir allocation strategies from the time of the first US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) through FDA approval

Conclusion
Pandemic response diverted routine ASP work and has not yet returned to baseline. Despite the reduction in pharmacy personnel due to the pandemic, the ASP pharmacy lead took on a novel and critical stewardship role throughout the pandemic exemplified by their involvement in novel treatment allocation for COVID patients.

Disclosures
Melissa D. Johnson, PharmD, MHS, Astellas (Consultant, Grant/Research Support)Charles River Laboratories (Grant/Research Support)Cidara (Consultant)Merck & Co (Consultant, Research Grant or Support)Paratek (Consultant)Pfizer (Consultant)Scynexis (Scientific Research Study Investigator)Theratechnologies (Consultant)UpToDate (Other Financial or Material Support, Author Royalties) Sonali D. Advani, MBBS, MPH, Nothing to disclose Rebekah W. Moehring, MD, MPH, UpToDate, Inc. (Other Financial or Material Support, Author Royalties)